Francois Marceau

Quebec, QC G1V4G2, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Non-peptide bradykinin B2 receptor ligands possessing the substituted quinolinyl moiety: Pharmacological properties and prospective clinical uses.

Non-peptide bradykinin B2 receptor ligands possessing the substituted quinolinyl moiety: Pharmacological properties and prospective clinical uses.

Journal: Peptides

Published: November 18, 2025

Non-peptide bradykinin B2 receptor ligands possessing the substituted quinolinyl moiety: pharmacological properties and prospective clinical uses.

Non-peptide bradykinin B2 receptor ligands possessing the substituted quinolinyl moiety: pharmacological properties and prospective clinical uses.

Journal: Peptides

Published: November 18, 2025

C5a receptor antagonism coming of age for vascular pathology.

C5a receptor antagonism coming of age for vascular pathology.

Journal: International immunopharmacology

Published: June 20, 2022

Are noscapine and raloxifene ligands of the bradykinin B2 receptor? An assessment based on the human umbilical vein contractility assay.

Are noscapine and raloxifene ligands of the bradykinin B2 receptor? An assessment based on the human umbilical vein contractility assay.

Journal: International immunopharmacology

Published: May 10, 2022

Picomolar Sensitivity Analysis of Multiple Bradykinin-Related Peptides in the Blood Plasma of Patients With Hereditary Angioedema in Remission: A Pilot Study.

Picomolar Sensitivity Analysis of Multiple Bradykinin-Related Peptides in the Blood Plasma of Patients With Hereditary Angioedema in Remission: A Pilot Study.

Journal: Frontiers in allergy

Published: December 16, 2021

In vitro pharmacological profile of PHA-022121, a small molecule bradykinin B2 receptor antagonist in clinical development.

In vitro pharmacological profile of PHA-022121, a small molecule bradykinin B2 receptor antagonist in clinical development.

Journal: International immunopharmacology

Published: November 16, 2021

Covid-19 challenges to immune investigations and therapies.

Covid-19 challenges to immune investigations and therapies.

Journal: International immunopharmacology

Published: March 18, 2021

A Robust Bioassay of the Human Bradykinin B2 Receptor that Extends Molecular and Cellular Studies: The Isolated Umbilical Vein.

A Robust Bioassay of the Human Bradykinin B2 Receptor that Extends Molecular and Cellular Studies: The Isolated Umbilical Vein.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: February 03, 2021

In Vitro Modeling of Bradykinin-Mediated Angioedema States.

In Vitro Modeling of Bradykinin-Mediated Angioedema States.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: July 17, 2020

Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants.

Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants.

Journal: Frontiers in medicine

Published: April 17, 2020

In Vitro Pharmacological Profile of a New Small Molecule Bradykinin B2 Receptor Antagonist.

In Vitro Pharmacological Profile of a New Small Molecule Bradykinin B2 Receptor Antagonist.

Journal: Frontiers in pharmacology

Published: March 16, 2020

The development of a targeted and more potent, anti-Inflammatory derivative of colchicine: Implications for gout.

The development of a targeted and more potent, anti-Inflammatory derivative of colchicine: Implications for gout.

Journal: Biochemical pharmacology

Published: March 05, 2020

Showing 1-12 of 48

Last Updated: 09/26/2026